192 related articles for article (PubMed ID: 38109924)
1. Study of cytokine-induced immunity in bullous pemphigoid: recent developments.
Huang R; Hu L; Jiang F
Ann Med; 2023; 55(2):2280991. PubMed ID: 38109924
[TBL] [Abstract][Full Text] [Related]
2. Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris.
Rico MJ; Benning C; Weingart ES; Streilein RD; Hall RP
Br J Dermatol; 1999 Jun; 140(6):1079-86. PubMed ID: 10354074
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of interleukin-9 in the serum of bullous pemphigoid: possible association with the pathogenicity of bullous pemphigoid.
Koga H; Teye K; Sugawara A; Tsutsumi M; Ishii N; Nakama T
Front Immunol; 2023; 14():1135002. PubMed ID: 37398641
[TBL] [Abstract][Full Text] [Related]
4. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.
Takamura S; Teraki Y
J Dermatol; 2022 Sep; 49(9):845-850. PubMed ID: 35538742
[TBL] [Abstract][Full Text] [Related]
5. Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid.
Chen F; Wang Y; Chen X; Yang N; Li L
Ann Med; 2023 Dec; 55(1):1156-1170. PubMed ID: 36999962
[No Abstract] [Full Text] [Related]
6. Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
de Graauw E; Sitaru C; Horn M; Borradori L; Yousefi S; Simon HU; Simon D
Allergy; 2017 Jul; 72(7):1105-1113. PubMed ID: 28135772
[TBL] [Abstract][Full Text] [Related]
7. Eosinophils in bullous pemphigoid.
Jones VA; Patel PM; Amber KT
Panminerva Med; 2021 Sep; 63(3):368-378. PubMed ID: 32536149
[TBL] [Abstract][Full Text] [Related]
8. The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease.
Amber KT; Valdebran M; Kridin K; Grando SA
Front Med (Lausanne); 2018; 5():201. PubMed ID: 30042946
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-26-DNA complexes promote inflammation and dermal-epidermal separation in a modified human cryosection model of bullous pemphigoid.
Mizuno Y; Shibata S; Ito Y; Taira H; Sugimoto E; Awaji K; Sato S
Front Immunol; 2022; 13():1013382. PubMed ID: 36311716
[TBL] [Abstract][Full Text] [Related]
10. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
Front Immunol; 2021; 12():569287. PubMed ID: 33841390
[TBL] [Abstract][Full Text] [Related]
11. IL-23/IL-17 Axis Activates IL-1β-Associated Inflammasome in Macrophages and Generates an Auto-Inflammatory Response in a Subgroup of Patients With Bullous Pemphigoid.
Le Jan S; Muller C; Plee J; Durlach A; Bernard P; Antonicelli F
Front Immunol; 2019; 10():1972. PubMed ID: 31507596
[TBL] [Abstract][Full Text] [Related]
12. The role of T cells in pemphigus vulgaris and bullous pemphigoid.
Fang H; Li Q; Wang G
Autoimmun Rev; 2020 Nov; 19(11):102661. PubMed ID: 32942041
[TBL] [Abstract][Full Text] [Related]
13. Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid.
Giomi B; Caproni M; Calzolari A; Bianchi B; Fabbri P
J Dermatol Sci; 2002 Nov; 30(2):116-28. PubMed ID: 12413767
[TBL] [Abstract][Full Text] [Related]
14. Eosinophil-derived galectin-10 upregulates matrix metalloproteinase expression in bullous pemphigoid blisters.
Sato T; Chiba T; Nakahara T; Watanabe K; Sakai S; Noguchi N; Noto M; Ueki S; Kono M
J Dermatol Sci; 2023 Oct; 112(1):6-14. PubMed ID: 37640566
[TBL] [Abstract][Full Text] [Related]
15. NET Formation in Bullous Pemphigoid Patients With Relapse Is Modulated by IL-17 and IL-23 Interplay.
Giusti D; Bini E; Terryn C; Didier K; Le Jan S; Gatouillat G; Durlach A; Nesmond S; Muller C; Bernard P; Antonicelli F; Pham BN
Front Immunol; 2019; 10():701. PubMed ID: 31019514
[No Abstract] [Full Text] [Related]
16. Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid.
Toosi S; Bystryn JC
Med Hypotheses; 2010 Apr; 74(4):727-8. PubMed ID: 19945799
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-16 expression and release in bullous pemphigoid.
Frezzolini A; Cianchini G; Ruffelli M; Cadoni S; Puddu P; De Pità O
Clin Exp Immunol; 2004 Sep; 137(3):595-600. PubMed ID: 15320912
[TBL] [Abstract][Full Text] [Related]
18. Association between TH2 Cytokine Gene Polymorphisms and Risk of Bullous Pemphigoid.
Tabatabaei-Panah PS; Moravvej H; Alirajab M; Etaaty A; Geranmayeh M; Hosseine F; Khansari A; Mahdian M; Mirhashemi M; Parvizi S; Sakhaie F; Ludwig RJ; Akbarzadeh R
Immunol Invest; 2022 Feb; 51(2):343-356. PubMed ID: 33047635
[TBL] [Abstract][Full Text] [Related]
19. High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities.
Sun CC; Wu J; Wong TT; Wang LF; Chuan MT
Br J Dermatol; 2000 Dec; 143(6):1235-40. PubMed ID: 11122027
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia.
Wakugawa M; Nakamura K; Hino H; Toyama K; Hattori N; Okochi H; Yamada H; Hirai K; Tamaki K; Furue M
Br J Dermatol; 2000 Jul; 143(1):112-6. PubMed ID: 10886144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
